These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 8849571

  • 1. Effect of follicle stimulating hormone or human chorionic gonadotrophin treatment on the production of gonadotrophin surge attenuating factor (GnSAF) during the luteal phase of the human menstrual cycle.
    Messinis IE, Lolis D, Zikopoulos K, Milingos S, Kollios G, Seferiadis K, Templeton AA.
    Clin Endocrinol (Oxf); 1996 Feb; 44(2):169-75. PubMed ID: 8849571
    [Abstract] [Full Text] [Related]

  • 2. Effect of varying concentrations of follicle stimulating hormone on the production of gonadotrophin surge attenuating factor (GnSAF) in women.
    Messinis IE, Lolis D, Papadopoulos L, Tsahalina T, Papanikolaou N, Seferiadis K, Templeton AA.
    Clin Endocrinol (Oxf); 1993 Jul; 39(1):45-50. PubMed ID: 8348707
    [Abstract] [Full Text] [Related]

  • 3. Activity of gonadotrophin surge-attenuating factor during the luteal phase in superovulated women.
    Messinis IE, MacTavish A, Templeton AA.
    J Reprod Fertil; 1993 Jan; 97(1):271-5. PubMed ID: 8464020
    [Abstract] [Full Text] [Related]

  • 4. Luteinizing hormone response to gonadotrophin-releasing hormone in normal women undergoing ovulation induction with urinary or recombinant follicle stimulating hormone.
    Messinis IE, Milingos S, Zikopoulos K, Hasiotis G, Seferiadis K, Lolis D.
    Hum Reprod; 1998 Sep; 13(9):2415-20. PubMed ID: 9806260
    [Abstract] [Full Text] [Related]

  • 5. Modulation of the action of gonadotrophin surge-attenuating factor by gonadotrophin-releasing hormone.
    Messinis IE, Lolis D, Zikopoulos K, Tsahalina E, Seferiadis K, Templeton AA.
    Hum Reprod; 1994 Aug; 9(8):1437-41. PubMed ID: 7989501
    [Abstract] [Full Text] [Related]

  • 6. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
    Kazem R, Messinis LE, Fowler P, Groome NP, Knight PG, Templeton AA.
    Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
    [Abstract] [Full Text] [Related]

  • 7. Changes in gonadotrophin response to gonadotrophin releasing hormone in normal women following bilateral ovariectomy.
    Alexandris E, Milingos S, Kollios G, Seferiadis K, Lolis D, Messinis IE.
    Clin Endocrinol (Oxf); 1997 Dec; 47(6):721-6. PubMed ID: 9497880
    [Abstract] [Full Text] [Related]

  • 8. Follicle stimulating hormone stimulates the production of gonadotrophin surge attenuating factor (GnSAF) in vivo.
    Messinis IE, Hirsch P, Templeton AA.
    Clin Endocrinol (Oxf); 1991 Nov; 35(5):403-7. PubMed ID: 1814653
    [Abstract] [Full Text] [Related]

  • 9. Attenuating activity of the ovary on LH response to GnRH during the follicular phase of the cycle.
    Dimitraki M, Messini CI, Dafopoulos K, Gioka T, Koutlaki N, Garas A, Georgoulias P, Messinis IE.
    Clin Endocrinol (Oxf); 2014 Mar; 80(3):439-43. PubMed ID: 23909480
    [Abstract] [Full Text] [Related]

  • 10. Changes in pituitary sensitivity to GnRH in estrogen-treated post-menopausal women: evidence that gonadotrophin surge attenuating factor plays a physiological role.
    Dafopoulos K, Kotsovassilis CG, Milingos S, Kallitsaris A, Galazios G, Zintzaras E, Sotiros P, Messinis IE.
    Hum Reprod; 2004 Sep; 19(9):1985-92. PubMed ID: 15229199
    [Abstract] [Full Text] [Related]

  • 11. Effect of an increase in FSH on the production of gonadotrophin-surge-attenuating factor in women.
    Messinis IE, Lolis D, Zikopoulos K, Tsahalina E, Seferiadis K, Templeton AA.
    J Reprod Fertil; 1994 Aug; 101(3):689-95. PubMed ID: 7966027
    [Abstract] [Full Text] [Related]

  • 12. Novel aspects of the endocrinology of the menstrual cycle.
    Messinis IE, Messini CI, Dafopoulos K.
    Reprod Biomed Online; 2014 Jun; 28(6):714-22. PubMed ID: 24745832
    [Abstract] [Full Text] [Related]

  • 13. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG, Macklon NS, Eijkemans MJ, Ludwig M, Felberbaum RE, Diedrich K, Bustion S, Loumaye E, Fauser BC.
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [Abstract] [Full Text] [Related]

  • 14. Pituitary gonadotrophin secretion during the first weeks of pregnancy.
    Jeppsson S, Rannevik G, Thorell JI.
    Acta Endocrinol (Copenh); 1977 May; 85(1):177-88. PubMed ID: 324219
    [Abstract] [Full Text] [Related]

  • 15. Variable effects of RU 486 on endometrial maintenance in the luteal phase extended by exogenous hCG.
    Croxatto HB, Salvatierra AM, Croxatto HD, Spitz IM.
    Clin Endocrinol (Oxf); 1989 Jul; 31(1):15-23. PubMed ID: 2598478
    [Abstract] [Full Text] [Related]

  • 16. Higher gonadotrophin surge-attenuating factor bioactivity is found in small follicles from superovulated women.
    Fowler PA, Fraser M, Cunningham P, Knight PG, Byrne B, McLaughlin EA, Wardle PG, Hull MG, Templeton A.
    J Endocrinol; 1994 Oct; 143(1):33-44. PubMed ID: 7964320
    [Abstract] [Full Text] [Related]

  • 17. The sequence of pituitary responses to synthetic luteinizing hormone releasing hormone (LH-RH) throughout the normal menstrual cycle.
    Grimes EM, Thompson IE, Taymor ML.
    Acta Endocrinol (Copenh); 1975 Aug; 79(4):625-34. PubMed ID: 1098349
    [Abstract] [Full Text] [Related]

  • 18. Women with poor response to IVF have lowered circulating gonadotrophin surge-attenuating factor (GnSAF) bioactivity during spontaneous and stimulated cycles.
    Martinez F, Barri PN, Coroleu B, Tur R, Sorsa-Leslie T, Harris WJ, Groome NP, Knight PG, Fowler PA.
    Hum Reprod; 2002 Mar; 17(3):634-40. PubMed ID: 11870115
    [Abstract] [Full Text] [Related]

  • 19. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
    Gerris J, De Vits A, Joostens M, Van Royen E.
    Hum Reprod; 1995 Jan; 10(1):56-62. PubMed ID: 7745071
    [Abstract] [Full Text] [Related]

  • 20. Suppression of luteal function by a luteinizing hormone-releasing hormone antagonist during the early luteal phase in the stumptailed macaque monkey and the effects of subsequent administration of human chorionic gonadotropin.
    Fraser HM, Nestor JJ, Vickery BH.
    Endocrinology; 1987 Aug; 121(2):612-8. PubMed ID: 3109885
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.